The passage of the U.S. health care reform bill does not seem to offer Indian generic-drug makers definite benefits because the measure contains provisions that would provide brand-name biotech drugmakers 12 years of market exclusivity and would prevent generic companies from entering settlement deals with pharmaceutical firms. However, the measure's proposed expansion of insurance coverage might benefit both generic and brand-name drugmakers.

Related Summaries